» Articles » PMID: 8054493

The Cognitive Abilities Screening Instrument (CASI): a Practical Test for Cross-cultural Epidemiological Studies of Dementia

Overview
Publisher Elsevier
Specialties Geriatrics
Psychiatry
Date 1994 Jan 1
PMID 8054493
Citations 359
Authors
Affiliations
Soon will be listed here.
Abstract

The Cognitive Abilities Screening Instrument (CASI) has a score range of 0 to 100 and provides quantitative assessment on attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, list-generating fluency, abstraction, and judgment. Scores of the Mini-Mental State Examination, the Modified Mini-Mental State Test, and the Hasegawa Dementia Screening Scale can also be estimated from subsets of the CASI items. Pilot testing conducted in Japan and in the United States has demonstrated its cross-cultural applicability and its usefulness in screening for dementia, in monitoring disease progression, and in providing profiles of cognitive impairment. Typical administration time is 15 to 20 minutes. Record form, manual, videotape of test administration, and quizzes to qualify potential users on the administration and scoring of the CASI are available upon request.

Citing Articles

Evaluating the Clinical Efficacy of an Exergame-Based Training Program for Enhancing Physical and Cognitive Functions in Older Adults With Mild Cognitive Impairment and Dementia Residing in Rural Long-Term Care Facilities: Randomized Controlled Trial.

Li A, Qiang W, Li J, Geng Y, Qiang Y, Zhao J J Med Internet Res. 2025; 27:e69109.

PMID: 39969990 PMC: 11888014. DOI: 10.2196/69109.


The impact of apolipoprotein E, type ∊4 allele on Alzheimer's disease pathological biomarkers: a comprehensive post-mortem pilot-analysis.

Wan Z, Ma T PLoS One. 2025; 20(2):e0303486.

PMID: 39913635 PMC: 11801730. DOI: 10.1371/journal.pone.0303486.


Neuropathological correlates of vulnerability and resilience in the cerebellum in Alzheimer's disease.

Samstag C, Chapman N, Gibbons L, Geller J, Loeb N, Dharap S Alzheimers Dement. 2024; 21(2):e14428.

PMID: 39713867 PMC: 11848203. DOI: 10.1002/alz.14428.


Brain Amyloid-β Peptide Is Associated with Pain Intensity and Cognitive Dysfunction in Osteoarthritic Patients.

Wen C, Kang H, Chan J Int J Mol Sci. 2024; 25(23.

PMID: 39684287 PMC: 11641244. DOI: 10.3390/ijms252312575.


The Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT) intervention: A personalized approach to dementia risk reduction.

Barnes D, Balderson B, Shulman L, Rosenberg D, Matson T, Mettert K J Alzheimers Dis. 2024; 102(4):1121-1132.

PMID: 39623940 PMC: 11875122. DOI: 10.1177/13872877241296161.